Evaluation of hepatitis B vaccine responsiveness in hemodialysis and peritoneal dialysis patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20150613Keywords:
End stage renal disease, Hepatitis B virus, VaccineAbstract
Background: Hepatitis B Virus (HBV) infection is considered as a major cause of liver cirrhosis and hepatocellular carcinoma. Patients with End Stage Renal Disease (ESRD) are a risk group for HBV infection. The vaccine of hepatitis B has been recommended for prevention of HBV infection in ESRD patient especially on renal replacement therapy.
Methods: Eighty seven patients with ESRD on peritoneal dialysis and hemodialysis requiring primary hepatitis B vaccination were enrolled in the study. Each of them received 40 µg of recombinant hepatitis B vaccine in a four-dose schedule. Antibody response was determined by the levels of antibodies to the hepatitis B surface antigen (anti-HBs) after last doses of the vaccination schedule.
Results: We observed three response patterns to the immunizations in all patients after vaccination, the nonresponders (24.7%) never reached the minimum protective titer of 10 mIU/mL, the poor responders (18.5%) had titers between 10 and 100 mIU/mL, and the good responders (56.8%) had antibody titers above 100 mIU/mL. Despite a reduction in anti-HBs over time, the good responders did not become unprotected during the observation period, especially those participants who had titers above 1000 mIU/mL after the initial immunization.
Conclusions: We concluded that the immune response of the HBV vaccine was reduced in the HD and PD patients, which need yearly re-evaluation of seroconversion with booster doses of HBV vaccination if needed.
References
Alter MJ, Arduino MJ, Lyerla HC, Miller ER, Tokars JI. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43.
Alavian SM, Bagheri-Lankarani K, Mahdavi-Mazdeh M, Nourozi S. Hepatitis B and C in dialysis units in Iran: changing the epidemiology. Hemodial Int. 2008;12(3):378-82.
Chau KF, Cheng YL, Tsang DN, Choi KS, Wong KM, Chak WL, et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am J Kidney Dis. 2004;43:910-7.
Goodman W, Gallagher N, Sherrard D. Peritoneal dialysis fluid as a source of hepatitis antigen. Nephron. 1981;29:107-9.
O’Connor J. Priorities for immunization against hepatitis. Br Med J. 1982;284:1876.
Drachman R, Isacsohn M, Rudensky B, Drukker A. Vaccination against hepatitis B in children and adolescent patients on dialysis. Nephrol Dial Transplant. 1989;4:372-4.
Ozener C, Fak AS, Avsar E, Cınar S, Lawrence R, Akoglu E. The effect of alpha interferon therapy and short interval intradermal administration on response to hepatitis B vaccine in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1339-40.
Center for Disease Control (CDC). Outbreaks of hepatitis B virus infection among hemodialysis patients, California, Nebraska, and Texas, 1994. MMWR. 1996;45:285-9.
Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, et al. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol. 2012;13:97.
Pin M, Compte MT, Angelet P, Gállego C, Gutiérrez C, Martinez Vea A. Long-term evaluation of immune response to hepatitis B vaccine in 136 patients undergoing hemodialysis. Nefrologia. 2009;29(5):415-20.
Mauri JM, Valles M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant. 1997;12:729-32.
El-Reshaid K, Al-Mufti S, Johny KV, Sugathan TN. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine. 1994;12:223-8.
Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis. 1991;11(2):73-83.
Kara IH, Yilmaz ME, Suner A, Kadiroglu AK, Isikoglu B. The evaluation of immune responses that occur after HBV infection and HBV vaccination in hemodialysis patients. Vaccine. 2004;22:3963-7.
Peces R, De la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in the hemodialysis patients. Am J Kidney Dis. 1997;29:239-45.
Cheng CH, Huang CC, Leu ML, Chiang CYF, Wu MS, Lai PC. Hepatitis B vaccine in hemodialysis patients with hepatitis C viral infection. Vaccine. 1997;15(12-13):1353-7.
Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection. Am J Nephrol. 1996;16:95-7.
Swan AM, DeVita MV. Higher response rate to hepatitis B vaccination observed in chronic hemodialysis patients. Clin Nephrol. 1997;47(3):207-8.
Radovic MM, Ostric V, Djukanovic L. Complete seroconversion after vaccination against hepatitis B virus in hemodialysis patients. Clin Nephrol. 1997;47(3):206-9.
Kroes AC, van Bommel EF, Kluytmans JA, Weimar W. Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of Bloodborne viruses. Infect Control Hosp Epidemiol. 1998;19(7):508-10.